Amadori 2013 |
APML excluded |
67 |
472 |
Induction and consolidation |
6 (induction), 3 (consolidation) |
2 (induction), 2 (consolidation) |
MICE (induction), ICE (consolidation) |
Same concomitant chemotherapy as in GO arm |
Burnett 2011 (induction randomisation) |
As above |
49 |
1113 |
Induction |
3 |
1 |
DA/ADE/FLAG-IDA |
As above |
Burnett 2011 (consolidation randomisation) |
As above |
46 |
948 |
Consolidation |
3 |
1 |
MACE/Ara-C |
As above |
Burnett 2012 (intensive trial) |
AML and high-risk MDS |
67 |
1115 |
Induction |
3 |
1 |
DA or d-Clo at induction (2–3 courses), Aza maintenance |
As above |
Burnett 2012 (low-intensity trial) |
AML, high-risk MDS |
75 |
495 |
Low intensity |
Flat dose of 5 |
4 |
Low-dose Ara-C 20 mg s/c injection |
As above |
Castaigne 2012 |
Primary AML |
62 |
280 |
Induction and consolidation |
3 |
3 (induction), 2 (consolidation) |
DA (1–2 courses at induction); two courses of DA as consolidation |
As above |
Delaunay 2011 ASH |
Intermediate-karyotype AML |
50 |
254 |
Induction and consolidation |
6 |
2 |
DA induction and MidAC intensive consolidation |
As above |
Fernandez 2011 |
APML excluded |
48 |
270 |
Consolidation |
6 |
1 |
None |
None |
Gamis 2013 ASH |
Primary AML |
9.9 |
1070 |
Induction and consolidation |
3 |
1 (induction), 1 (consolidation) |
ADE at induction and mitoxantrone/Ara-C at second consolidation |
Same concomitant chemotherapy as in GO arm |
Hasle 2012 |
Standard/high-risk disease in CR1 post-consolidation |
Not reported |
120 |
Maintenance |
5 |
2 |
None |
None |
Lowenberg 2010 |
APML excluded |
67 |
232 |
Maintenance |
6 |
3 |
None |
None |
Petersdorf 2013 (induction randomisation) |
As above |
47 |
595 |
Induction |
6 |
1 |
DA (45 mg/m2 daunorubicin) |
DA (60 mg/m2 daunorubicin) |
Petersdorf 2013 (maintenance randomisation) |
As above |
Not reported |
174 |
Maintenance |
5 |
3 |
None |
None |